Gynecomastia in patients with prostate cancer. a systematic review
| Autor: | Lina Palangi, Anders Fagerlund, Fabio Santanelli di Pompeo, Luigi Cormio, Anna Elander, Richard Lewin, Gennaro Selvaggi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Male
Oncology medicine.medical_specialty Bicalutamide MEDLINE lcsh:Medicine Anastrozole Cochrane Library Prostate cancer Meta-Analysis as Topic Quality of life Internal medicine medicine Humans lcsh:Science Multidisciplinary business.industry lcsh:R Prostatic Neoplasms Androgen Antagonists medicine.disease Gynecomastia Quality of Life bicalutamide indiced gynecomastia prophylactic breast irradiation tamoxifen lcsh:Q business Tamoxifen Research Article medicine.drug |
| Zdroj: | PLoS ONE PLoS ONE, Vol 10, Iss 8, p e0136094 (2015) |
| Popis: | Introduction Gynecomastia and/or mastodynia is a common medical problem in patients receiving antiandrogen (bicalutamide or flutamide) treatment for prostate cancer; up to 70% of these patients result to be affected; furthermore, this can jeopardise patients’ quality of life. Aims To systematically review the quality of evidence of the current literature regarding treatment options for bicalutamide-induced gynecomastia, including efficacy, safety and patients’ quality of life. Methods The PubMed, Medline, Scopus, The Cochrane Library and SveMed+ databases were systematically searched between January 1, 2000 and December 31, 2014. All searches were undertaken between January and February 2015. The search phrase used was:”gynecomastia AND treatment AND prostate cancer”. Two reviewers assessed 762 titles and abstracts identified. The search and review process was done in accordance with the PRISMA statement. The PICOS (patients, intervention, comparator, outcomes and study design) process was used to specify inclusion criteria. Quality of evidence was rated according to GRADE. Main Outcome Measures Primary outcomes were: treatment effects, number of complications and side effects. Secondary outcome was: Quality of Life. Results Eleven studies met the inclusion criteria and are analysed in this review. Five studies reported pharmacological intervention with tamoxifen and/or anastrozole, either as prophylactic or therapeutic treatment. Four studies reported radiotherapy as prophylactic and/or therapeutic treatment. Two studies compared pharmacological treatment to radiotherapy. Most of the studies were randomized with varying risk of bias. According to GRADE, quality of evidence was moderate to high. Conclusions Bicalutamide-induced gynecomastia and/or mastodynia can effectively be managed by oral tamoxifen (10–20 mg daily) or radiotherapy without relevant side effects. Prophylaxis or therapeutic treatment with tamoxifen results to be more effective than radiotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|